REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer

Lee et al . (1) evaluated the efficacy and safety of bevacizumab in combination with single-agent chemotherapy for platinum-resistant ovarian cancer in a large retrospective analysis involving Korean women with platinum-resistant recurrent ovarian cancer from 27 different institutions.

[1]  Cesar M. Castro,et al.  Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. , 2019, JAMA oncology.

[2]  E. Swisher,et al.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.

[3]  B. Monk,et al.  Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial , 2019, Gynecologic Oncology.

[4]  J. W. Kim,et al.  Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). , 2019, Gynecologic oncology.

[5]  V. Gebski,et al.  Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Tinker,et al.  Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2 , 2017 .

[7]  C. Hudis,et al.  The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. , 2017, European journal of cancer.

[8]  Jian-Bing Fan,et al.  Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes , 2017, Clinical Cancer Research.

[9]  R. Wenham,et al.  Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives , 2016, International journal of women's health.

[10]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.